000756.SZ
Shandong Xinhua Pharmaceutical Co., Ltd.
SZSE · Healthcare · C 制造业 · CN
CNY 12.36
+0.41%Oct 28, 2026, 08:52 UTC
Shandong Xinhua Pharmaceutical reported first-three-quarter 2026 revenue of RMB6.061 billion, down 10.38% year over year, and net profit of RMB195 million, down 23.88%, with earnings per share of RMB0.28.
Source:Oct 28, 2026, 08:46 UTC
Shandong Xinhua Pharmaceutical Company Limited reported nine-month net profit attributable to shareholders of RMB195 million, down 23.88% year over year, and earnings per share of RMB0.28.
Source:Oct 19, 2026, 09:31 UTC
China's National Medical Products Administration approved Xinhua Pharmaceutical's supplemental application for nimodipine tablets, which passed the generic drug quality and efficacy consistency evaluation.
Source:Oct 13, 2026, 14:24 UTC
Ten A-share listed companies disclosed plans to reduce their holdings; no listed company disclosed a planned increase in holdings that day.
Source:Oct 13, 2026, 09:24 UTC
Xinhua Pharmaceutical board secretary Cao Changqiu plans to reduce his company shareholding by no more than 83,300 shares through centralized bidding from November 5, 2026, to February 4, 2027, representing 0.012% of total shares.
Source:Oct 8, 2026, 09:03 UTC
China's National Medical Products Administration approved registration of Xinhua Pharmaceutical's sacubitril valsartan sodium tablets in October 2026.
Source:Sep 29, 2026, 12:09 UTC
Xinhua Pharmaceutical announced that Deputy General Manager Liu Xuesong resigned from his position and all other roles at the company due to a work reassignment, effective upon delivery of his resignation to the board.
Source:Sep 29, 2026, 09:07 UTC
Shandong Xinhua Pharmaceutical appointed Yang Sujuan as deputy general manager, with her term running from board approval until the end of the 11th board's term.
Source:Sep 21, 2026, 09:58 UTC
China's A-share major indices closed higher on September 21, 2026, with the Shanghai Composite up 0.97% at 3949.91, the Shenzhen Component up 0.65% at 13730.02, and the ChiNext up 0.80% at 3399.59, as over 4,500 stocks advanced and innovative drug concept stocks surged.
Source:Sep 20, 2026, 07:34 UTC
Shandong Zibo Xinda Pharmaceutical, a wholly owned subsidiary of Shandong Xinhua Pharmaceutical, received a drug registration certificate from China's National Medical Products Administration for 5mg donepezil hydrochloride orally disintegrating tablets.
Source:Sep 18, 2026, 09:16 UTC
Shandong Xinhua Pharmaceutical received drug registration certificates from China's National Medical Products Administration for its oral concentrated solution of magnesium sulfate, sodium sulfate and potassium sulfate and oral levocarnitine solution.
Source:Aug 31, 2026, 08:48 UTC
Xinhua Pharmaceutical's wholly-owned subsidiary Shandong Zibo Xinda Pharmaceutical received approval for its azithromycin tablets 0.25g to pass generic drug consistency evaluation, enabling market entry.
Source:Aug 28, 2026, 08:18 UTC
Xinhua Pharmaceutical received a drug registration certificate from China's National Medical Products Administration for its dapoxetine hydrochloride tablets, a 30mg Class 4 chemical prescription drug for treating premature ejaculation in men aged 18-64, approved in August 2026.
Source:Aug 25, 2026, 09:06 UTC
Xinhua Pharmaceutical announced its interim results for the six months ended June 2026, with revenue of RMB 4.358 billion, down 6.06% year-on-year, and net profit of RMB 149 million, down 33.35% year-on-year.
Source:Aug 21, 2026, 08:53 UTC
Xinhua Pharmaceutical announced that it received the Drug Registration Certificate for Dapagliflozin Tablets from the National Medical Products Administration in August 2026, following its application submitted to CDE in March 2025.
Source:Jul 4, 2026, 00:38 UTC
Xinhua Pharmaceutical initiated the Phase I clinical trial of its first-in-class innovative drug LXH-1211 tablets for pulmonary arterial hypertension.
Source: